Himachal Pradesh high court restrains DRL from selling BI's diabetic drug Jardiance

The drugmaker said it is reviewing legal options including filing an appeal against the court order. Dr Reddy's has launched copies of Jardiance (empagliflozin), which has valid patent in India until 2025. BI has sought restraining order on manufa...

Dr Reddy's on Thursday said Himachal Pradesh high court has issued an interim injunction restraining them from manufacturing and selling generic version of German drug maker Boehringer Ingelheim's (BI) diabetes drug Jardiance.

The drugmaker said it is reviewing legal options including filing an appeal against the court order.

Dr Reddy's has launched copies of Jardiance (empagliflozin), which has valid patent in India until 2025. BI has sought restraining order on manufacture and sale of the drug.


Jardiance is top-selling drug for BI in India.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › Industry › Healthcare/Biotech › Pharmaceuticals › Himachal Pradesh high court restrains DRL from selling BI's diabetic drug Jardiance
Text Size:AAA
Success
This article has been saved

*

+